RIVANNA, a developer of medical imaging solutions, has received $30.5 million in funding from the Biomedical Advanced Research and Development Authority (BARDA) to support the further development of its Accuro XV for musculoskeletal diagnostics. The funding will also be used to submit an application for FDA clearance. RIVANNA has already completed its base-stage performance milestones ahead of schedule, which allowed for the early option funding. The company's Accuro XV integrates ultrasound-based bone and 3D soft-tissue imaging technology with AI-enabled software, offering advantages over traditional X-ray methods. The funding from BARDA includes options for additional funding up to $56.4 million to support the development of AI-enabled fracture detection. The project aims to develop an FDA-cleared product for expedited triage of low-acuity extremity injuries, particularly in mass-casualty blast trauma incidents.
Fri, 28 Jul 2023 16:57:41 GMT | BioSpace